Related Experiment Video
Updated: Aug 12, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
The Heart Failure Optimization Study (HF-OPT): rationale and design
Insights
This study evaluates left ventricular function recovery in heart failure patients after 3 months of optimal medical therapy. Results may influence decisions on implantable cardioverter-defibrillator implantation for primary prevention.
Area of Science:
- Cardiology
- Heart Failure Research
- Medical Device Technology
Background:
- Current guidelines recommend delaying implantable cardioverter-defibrillator (ICD) implantation for primary prevention in heart failure with reduced ejection fraction (HFrEF) until optimal guideline-directed medical therapy (GDMT) is achieved for at least 3 months.
- Optimizing GDMT can extend beyond the initial 3-month period, necessitating further evaluation of cardiac function recovery.
- The Heart Failure Optimization Study (HF-OPT) addresses the need to understand left ventricular function recovery beyond this initial 3-month timeframe in newly diagnosed HFrEF patients.
Purpose of the Study:
- To assess the recovery of left ventricular ejection fraction (LVEF) in patients with newly diagnosed HFrEF.
- To evaluate the rate of LVEF improvement beyond 3 months of optimized GDMT.
- To determine if LVEF can recover to >35% between 90 and 180 days post-diagnosis.
Main Methods:
- The HF-OPT is a multicenter study with two non-randomized phases: a registry and a study phase.
- Patients receive a wearable cardioverter-defibrillator (WCD) for the first 90 days and are enrolled in a pre-study registry.
- Eligible patients undergo LVEF reassessment at 90, 180, and 360 days post-discharge. Approximately 600 subjects are planned for the study portion.
Main Results:
- The primary objective is to measure the rate of LVEF recovery to >35% between 90 and 180 days.
- Secondary endpoints include monitoring all-cause mortality and analyzing data from the WCD regarding arrhythmias and shocks.
- Approximately one-third of the ~600 enrolled subjects are expected to have reduced LVEF at the start of the study phase (day 90).
Conclusions:
- The HF-OPT study will provide crucial data on LVEF recovery rates between 90 and 180 days in HFrEF patients undergoing GDMT titration.
- Findings may inform clinical decisions regarding the timing and necessity of primary prophylactic ICD implantation.
- Understanding functional recovery is key to refining treatment strategies for HFrEF.
Background:
According to the current guidelines, implantable cardioverter-defibrillators (ICD) for primary prevention in patients with heart failure and reduced ejection fraction (HFrEF) should not be considered until optimal guideline-directed medical therapy (GDMT) has been achieved for a minimum of 3 months. Optimization of GDMT often needs time beyond 3 months after diagnosis. The aim of the Heart Failure Optimization Study (HF-OPT) is to evaluate the recovery of left ventricular function beyond 3 months after diagnosis of newly diagnosed HFrEF.
Methods:
The HF-OPT multicenter study is comprised of two non-randomized phases (registry and study). During the first 90 days a wearable cardioverter-defibrillator (WCD) is prescribed and patients are enrolled in an observational pre-study registry. Registry subjects meeting inclusion criteria for the study portion at day 90 have ongoing left ventricular ejection fraction (LVEF) reassessment at 90, 180 and 360 days after the index hospital discharge, regardless of continued WCD use. Approximately 600 subjects will be enrolled in the study portion. Of those, one-third are anticipated to start the study phase at day 90 with reduced LVEF. The primary objective of this study is to observe the rate of recovery of LVEF > 35% between 90 and 180 days, while key secondary endpoints include mortality and WCD recorded arrhythmias and shocks.
Discussion:
The HF-OPT study will provide important information on the rate of additional recovery of LVEF > 35%, between 90 and 180 days, in newly diagnosed HF with reduced LVEF patients being titrated with GDMT. The results of the study may impact indications for primary prophylactic ICD implantation.
More Related Videos
07:13A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
Published on: April 30, 2020
07:49Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure VII: Nursing Interventions